ABSTRACT OF THE INVENTION

This application is directed to compounds of the formula



wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W^1 and W^2 are independently -O- or -$S(=O)_t$- , where t is 0, 1, or 2; Y is $=C(R^1{}_a)$-, where $R^1{}_a$ is a member selected from the group consisting of H; F; Cl; CN; NO_2; -(C_1-C_4) alkyl; -(C_2-C_4) alkynyl; fluorinated-(C_1 -C_3) alkyl; fluorinated-(C_1 -C_3) alkoxy; $-OR^{16}$; and $-C(=O)NR^{22}{}_aR^{22}{}_b$; $R^{22}{}_a$ and $R^{22}{}_b$ are defined as set forth in the specification; $-R^A$ and R^B are each a member independently selected from the group consisting of H; F; CF_3; -(C_1-C_4) alkyl; -(C_3-C_7) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R^{10}, which is defined as set forth in the specification; R^{16} and R^{17} are defined as set forth in the specification; $-R^C$ and R^D have the same meaning as defined above for R^A and R^B except that one of them must be -H, and they are selected independently of each other and of R^A and R^B; R^1 and R^2 are each a member independently selected from the group consisting of H; F; Cl; CN; NO_2; -(C_1-C_4) alkyl; -(C_2-C_4) alkynyl; fluorinated-(C_1 -C_3)alkyl; OR^{16}; and $-C(=O)NR^{22}{}_aR^{22}{}_b$; $-R^3$ is H; -(C_1-C_3)alkyl; phenyl; benzyl; or OR^{16}; R^4, R^5 and R^6 are defined as set forth in the specification; J^1 and J^2 are each independently a moiety comprising a saturated or unsaturated six-membered monocyclic carbon ring; and D is a member independently selected from the group consisting of partial Formulas (1.1.1) through (1.1.5) as set forth in the specification; a pharmaceutically acceptable salt thereof; which are useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease.